Uncovering the role of chromosome 21 in Down syndrome-associated leukemias
Uncovering the role of chromosome 21 in Down syndrome-associated leukemias
Dr. Jason Sheltzer, Ph.D. – Yale University, New Haven, CT
Targeting oncogenic transcriptional programs in Juvenile Myelomonocytic Leukemia
Targeting oncogenic transcriptional programs in Juvenile Myelomonocytic Leukemia
Dr. Julia Maxson, Ph.D. – Oregon Health & Science University – OHSU, Portland, OR
Cooperative mutagenesis driving pediatric pre-B cell leukemia
Cooperative mutagenesis driving pediatric pre-B cell leukemia
Dr. Abby Green, M.D. – Washington University, School of Medicine, St. Louis, MO
The impact of UBTF Tandem Duplications in Pediatric Acute Myeloid Leukemia
The impact of UBTF Tandem Duplications in Pediatric Acute Myeloid Leukemia
Dr. lannis Aifantis, Ph.D. – New York University Grossman School of Medicine, New York, NY
CAR gamma delta T cell-based multi-pronged immunotherapy for AML
CAR gamma delta T cell-based multi-pronged immunotherapy for AML
Dr. Norihiro Watanabe, Ph.D. – Baylor College of Medicine
Dietary valine modulation to enhance therapies for high-risk T-ALL
Dietary valine modulation to enhance therapies for high-risk T-ALL
Dr. Palaniraja Thandapani, Ph.D. – University of Texas M.D. Anderson Cancer Center, Houston, TX
A PHASE 1 STUDY OF REVUMENIB, AZACITIDINE, AND VENETOCLAX AND IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA
A PHASE 1 STUDY OF REVUMENIB, AZACITIDINE, AND VENETOCLAX AND IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA
Dr. Hiroto Inaba, M.D. – St. Jude Children's Research Hospital, Inc., Memphis, TN
Validating PRL2 as a New Therapeutic Target in T-ALL
Validating PRL2 as a New Therapeutic Target in T-ALL
Dr. Loretta Li, M.D. – Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL
Targeting RNA Condensates in Pediatric Myeloid Leukemia
Targeting RNA Condensates in Pediatric Myeloid Leukemia
Dr. Bruno Di Stefano, Ph.D. – Baylor College of Medicine, Houston, TX
Modeling relapsed hypodiploid B-cell acute lymphoblastic leukemia using humanized in vivo systems
Modeling relapsed hypodiploid B-cell acute lymphoblastic leukemia using humanized in vivo systems
Dr. Matthew Witkowski – University of Colorado Denver, AMC and DC
Targeting the HMGA1 Chromatin Regulator in MLL1-Rearranged Pediatric Leukemia
Targeting the HMGA1 Chromatin Regulator in MLL1-Rearranged Pediatric Leukemia
Dr. Linda Resar – Johns Hopkins University School of Medicine, Baltimore, MD
Discovery of novel MDM2-targeted therapy for pediatric AML
Discovery of novel MDM2-targeted therapy for pediatric AML
Dr. Muxiang Zhou – Emory University, Atlanta, GA
Role of PAX5 mutations in B-cell acute lymphoblastic leukemia
Role of PAX5 mutations in B-cell acute lymphoblastic leukemia
Dr. Zhaohui Gu – Beckman Research Institute of the City of Hope, Duarte, CA
Activating type I interferon-driven immune surveillance to treat pediatric B-cell acute lymphoblastic leukemia
Activating type I interferon-driven immune surveillance to treat pediatric B-cell acute lymphoblastic leukemia
Beckman Research Institute of the City of Hope, Duarte, CA
Targeting the IKAROS-SAMHD1 axis in KMT2A rearranged B-ALL
Targeting the IKAROS-SAMHD1 axis in KMT2A rearranged B-ALL
Baylor College of Medicine, Houston, TX
Characterizing the ENL YEATS epigenetic reading domain as a therapeutic target in pediatric MLL-ENL leukemias
Characterizing the ENL YEATS epigenetic reading domain as a therapeutic target in pediatric MLL-ENL leukemias
The Regents of the University of Michigan, Ann Arbor, MI
Development of anti-KIT antibodies and immunotoxins as therapeutics and HSCT conditioning agents for pediatric acute myeloid leukemia
Development of anti-KIT antibodies and immunotoxins as therapeutics and HSCT conditioning agents for pediatric acute myeloid leukemia
Stanford University, Stanford, CA
Polycomb inhibition sensitizes AML to anthracycline therapy
Polycomb inhibition sensitizes AML to anthracycline therapy
The Research Institute at Nationwide Children’s Hospital, Columbus, OH
L3MBTL3, A Therapeutic Target in Acute Myeloid Leukemia
L3MBTL3, A Therapeutic Target in Acute Myeloid Leukemia
The Regents of the University of Michigan, Ann Arbor, MI
Targeting Signaling Pathways that Confer Cytarabine Resistance in Pediatric AML
Targeting Signaling Pathways that Confer Cytarabine Resistance in Pediatric AML
Baylor College of Medicine, Houston, TX